These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 12505833)
21. omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Zanarini MC; Frankenburg FR Am J Psychiatry; 2003 Jan; 160(1):167-9. PubMed ID: 12505817 [TBL] [Abstract][Full Text] [Related]
22. Treating prodromal episodes to prevent relapse in schizophrenia. Herz MI; Glazer W; Mirza M; Mostert M; Hafez H Br J Psychiatry Suppl; 1989 Jul; (5):123-7. PubMed ID: 2574984 [No Abstract] [Full Text] [Related]
23. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment. Morrissette DA; Stahl SM CNS Spectr; 2012 Nov; 17 Suppl 1():10-21. PubMed ID: 23462201 [TBL] [Abstract][Full Text] [Related]
24. Use of Omega-3 Polyunsaturated Fatty Acids as Augmentation Therapy in Treatment-Resistant Schizophrenia. Cuéllar-Barboza AB; Sánchez-Ruiz JA; Corral PM Prim Care Companion CNS Disord; 2017 May; 19(3):. PubMed ID: 28472557 [No Abstract] [Full Text] [Related]
25. Omega-3 fatty acids and depression: from cellular mechanisms to clinical care. Freeman MP; Rapaport MH J Clin Psychiatry; 2011 Feb; 72(2):258-9. PubMed ID: 21382308 [No Abstract] [Full Text] [Related]
26. Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia. Yao JK; Magan S; Sonel AF; Gurklis JA; Sanders R; Reddy RD Prostaglandins Leukot Essent Fatty Acids; 2004 Sep; 71(3):171-6. PubMed ID: 15253886 [TBL] [Abstract][Full Text] [Related]
27. [Omega-3 fatty acids in cardiology. Latest developments]. von Schacky C MMW Fortschr Med; 2007 Sep; 149 Suppl 3():97-101. PubMed ID: 17955786 [TBL] [Abstract][Full Text] [Related]
28. Can clinical practice guide a research agenda? Marder SR Schizophr Bull; 2002; 28(1):127-9. PubMed ID: 12047012 [TBL] [Abstract][Full Text] [Related]
29. Switching antipsychotic medications: a 2-year chart-review study exploring patient characteristics and psychiatric service use of schizophrenia patients. Schneider AL; Mosier KE; Tempier RP J Clin Psychiatry; 2009 Jun; 70(6):937-9. PubMed ID: 19573492 [No Abstract] [Full Text] [Related]
30. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Woods SW; Gueorguieva RV; Baker CB; Makuch RW Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728 [TBL] [Abstract][Full Text] [Related]
31. Omega-3 fatty acids: time to get the messages right! Calder PC; Deckelbaum RJ Curr Opin Clin Nutr Metab Care; 2008 Mar; 11(2):91-3. PubMed ID: 18301081 [No Abstract] [Full Text] [Related]
32. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Heinrichs RW Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745 [No Abstract] [Full Text] [Related]
39. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Lieberman JA Arch Gen Psychiatry; 2006 Oct; 63(10):1069-72. PubMed ID: 17015808 [No Abstract] [Full Text] [Related]
40. [Acute phase drug therapy and drug switching in the treatment of patients with schizophrenia]. Fujii Y Seishin Shinkeigaku Zasshi; 2001; 103(12):1030-5. PubMed ID: 11925840 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]